NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16

6h ago🟠 Likely Overhyped
Share𝕏inf

Alpha Tau reports 100% objective response in six glioblastoma patients, but data is early.

What the company is saying

Alpha Tau Medical Ltd. is highlighting interim results from its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma, emphasizing that all six patients who reached response assessment achieved an objective response by MRI. The company stresses that 100% of planned Alpha DaRT sources were successfully deployed in all eight treated patients, with no unanticipated serious adverse events observed. CEO Uzi Sofer and Chief Medical Officer Dr. Robert Den frame the results as exceeding expectations for such a difficult cancer, using language like 'transformational' and 'incredibly encouraging.' The announcement underscores that all treated patients are alive, and five of six evaluable patients (83.3%) achieved a complete response, with the remaining patient (16.7%) showing a 58% tumor reduction. The company is open about the trial's primary endpoints—feasibility and safety—and acknowledges that responses in recently assessed patients are early and require confirmation. The tone is optimistic, with forward-looking statements about ongoing enrollment toward 20 patients and the potential for these results to support future market submission.

What the data suggests

The disclosed data shows that as of November 11, 2026, eight patients have been treated in the REGAIN trial, with six reaching response assessment. All six evaluable patients achieved an objective response by RANO criteria: five (83.3%) had a complete response and one (16.7%) had a partial response with a 58% tumor reduction. All eight patients were alive at the data cutoff, and no unanticipated serious adverse events occurred; one grade 3 SAE (seizure with Todd’s paralysis) resolved fully. Median follow-up among the six assessed patients is 6.9 months (range 3.1–11.6), and median overall survival has not been reached. No definitive recurrence within the treated area has been reported. The trial is ongoing, with a target enrollment of up to 20 patients, and the current results are interim, with some responses still subject to confirmation on future scans. The data is robust for an early-stage trial but is based on a small cohort and limited follow-up.

Analysis

The announcement presents positive interim clinical trial results, with all six evaluable patients showing objective responses and no unanticipated serious adverse events. The language is upbeat and highlights early efficacy, but the trial is still ongoing with only eight patients treated out of a planned 20, and median follow-up is short (median 6.9 months). Several forward-looking statements discuss potential regulatory submissions and future patient outcomes, but these are not yet realised and remain subject to confirmation as more data matures. No financial, revenue, or profitability metrics are disclosed, and there is no mention of immediate commercial impact or capital outlay tied to these results. The gap between narrative and evidence is moderate: while the clinical data is promising, the sample size is small, follow-up is limited, and the ultimate benefit or regulatory outcome is uncertain and likely long-term. The tone is optimistic but generally proportionate to the disclosed results, with some inflation in projecting future regulatory milestones based on early data.

Risk flags

  • ●The small sample size (six evaluable patients) and short median follow-up (6.9 months) limit the reliability of efficacy and safety conclusions; early results in small cohorts often do not predict outcomes in larger, more diverse populations.
  • ●Some responses are based on early assessments and require confirmation on subsequent scans, introducing uncertainty about the durability and reproducibility of the observed effects.
  • ●The trial is ongoing, with only eight of a planned 20 patients treated, so the final results may differ materially from these interim findings; enrollment and follow-up delays or unexpected adverse events could alter the risk/benefit profile.
  • ●No financial data, cash runway, or funding plan is disclosed, yet the company references the need for additional funding and costs of being public, indicating potential future capital requirements and dilution risk.
  • ●Necrosis or suspected necrosis was observed in four of six assessed patients, which, while asymptomatic so far, could become clinically significant with longer follow-up or in a larger cohort.

Bottom line

Alpha Tau's interim REGAIN trial results show a 100% objective response rate in six glioblastoma patients, with 83.3% achieving complete response and no unanticipated serious adverse events. All eight treated patients are alive, and the therapy was successfully delivered in every case, but the dataset is small and follow-up is short. The company is positioning these results as a potential basis for regulatory submission, but this is premature until the trial completes enrollment and longer-term outcomes are available. Investors should recognize that while the early efficacy signals are promising, the ultimate clinical and commercial impact remains unproven and will depend on durability of response, safety in a larger cohort, and regulatory acceptance. The most important takeaway is that this is an early signal, not a definitive breakthrough, and further data will be needed before any value inflection is likely.

Announcement summary

(NASDAQ:DRTS) Alpha Tau Medical Ltd. announced updated interim results from its U.S. REGAIN trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), as of November 11, 2026. The results were presented at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia by the study team from The Ohio State University Comprehensive Cancer Center (OSUCCC - James). Eight patients have been treated in the trial to date, and six have reached response assessment. The primary endpoints of the REGAIN trial are feasibility and safety. Planned Alpha DaRT sources were successfully deployed in all eight patients treated to date (100%). No unanticipated serious adverse events (SAEs) have been observed. One grade 3 SAE, previously reported in May 2026, was a seizure with Todd’s paralysis in a patient with a prior history of seizures, requiring a 48-hour hospital stay and resolved with steroids. All patients recovered from any adverse events without residual procedure-related symptoms. All eight treated patients were alive as of November 11, 2026. Among the six patients who have reached response assessment, the median follow-up from trial enrollment was 6.9 months (range 3.1 to 11.6 months), and median overall survival has not been reached. Three of these patients have now been followed for more than eight months from enrollment. All six evaluable patients (100%) achieved an objective response by MRI using RANO criteria: five patients (83.3%) achieved a complete response with no measurable tumor remaining at the treated site, and one patient (16.7%) achieved a partial response with a 58% decrease in tumor measurements. The first three patients, initially reported as two complete responses and one stable disease in May 2026, have all now been assessed as confirmed complete responses. The responses in the three most recently assessed patients were observed at early assessments and remain subject to confirmation on subsequent scans. No definitive recurrence within the treated area has been reported in any patient as of the cutoff date. One patient developed tumor progression away from the treated area approximately nine months after treatment while remaining free of recurrence in the treated area and has received additional therapy. Follow-up imaging has shown necrosis or suspected necrosis in or around the treated area in four of the six patients who have reached response assessment; this necrosis has been asymptomatic and none of these findings was a serious adverse event. In two patients, recent scans showed new or increased enhancement adjacent to or outside the treated area, and investigators cannot yet determine whether these findings represent necrosis or tumor progression; these patients are being evaluated with additional imaging and, as needed, biopsy. The REGAIN trial is designed to enroll up to 20 patients, and enrollment and follow-up are ongoing. The patients were treated at OSUCCC - James in Columbus, Ohio, by a multidisciplinary team led by Principal Investigator and Radiation Oncologist Joshua D. Palmer, MD, Medical Physicist Michael Degnan, MS, DABR, and Neurosurgeon J. Bradley Elder, MD, using a novel stereotactic delivery approach designed by Alpha Tau for intracranial use. Alpha Tau will host a conference call with management and Dr. Joshua Palmer on November 16, 2026, at 8:30 am ET. The REGAIN study is a prospective, open-label, single arm interventional study designed to evaluate the feasibility and safety of Alpha DaRT for the potential treatment of recurrent glioblastoma, with a planned enrollment of up to 20 U.S. patients.

Disagree with this article?

Ctrl + Enter to submit